Earlier today SL-401, Stemline Therapeutics' lead compound, received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). The new drug candidate has completed a multi-center Phase I/II clinical trial in AML where it has demonstrated single agent efficacy, including two durable complete responses (CRs), multiple blast reductions and disease stabilizations, and…

TRX518, a novel, first-in-class immunomodulatory agent demonstrates anti-tumor activity in data presented at the Keystone Symposia ‘Antibodies as Drugs’ meeting held from February 6 - 11, 2011 in Keystone, Colorado.



TRX518 is an investigational monoclonal antibody reactive withthe glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed…

Data on the clinical and preclinical development of ENMD-2076, published in the December 3, 2010 on-line issue of the American Association for Cancer Research (AACR) journal, Clinical Cancer Research, is expected appear in an upcoming edition of the publication.



ENMD-2076, which is being developed by EntreMed Inc. , a clinical-stage pharmaceutical company, is an orally-active, Aurora A/angiogenic kinase…

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for…

A Phase II trial with an investigational therapy called DCVax® (Northwest Biotherapeutics), a personalized vaccine that takes a patient’s immune cells and the biomarkers from that patient’s tumor tissue to mobilize the full immune system response to recognize and kill the tumor cells, resumes enrollment.



The purpose of the ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical…

San Francisco based Jennerex, Inc., a private clinical-stage biotherapeutics company and Transgene , a member of the Institut Merieux Group initiated the enrollment and treatment of patients in a Phase 1b clinical trial to evaluate JX-594 (Vaccinia GM-CSF/thymidine kinase-deactivated virus…

Top-line results from the pivotal phase III '147 study evaluating denosumab (Xgeva™, Amgen) versus placebo in 1,432 men with castrate-resistant prostate cancer demonstrated that the new drug significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary…

The combination of pertuzumab (Omnitarg, Genentech) and trastuzumab (Herceptin, Genentech) had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.



Pertuzumab is a monoclonal antibody. It is the first of its class in a line of…

A randomized, prospective study, published online December 6, 2010, in the Journal of Clinical Oncology found that regular use of sunscreen reduced the risk of developing melanoma – the deadliest form of skin cancer – by half, including a 73% drop in risk for invasive melanoma The study included more than 1,600 adults participates in Australia.



“Our…

A Phase II clinical trial of SG2000 in ovarian cancer, being sponsored by the National Cancer Institute (NCI), is now actively recruiting patients for treatment for the treatmet of various forms of ovarian cancer

Ovarian cancer is the sixth most commonly diagnosed cancer in women and the eighth leading cause of cancer death among women worldwide, according to the American Cancer Society. Annually, an estimated 230,000 women are diagnosed with ovarian cancer around the world…